Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology (NANOPI)

Centre Hospitalier Universitaire de Saint Etienne

Status: Completed

Conditions: Interstitial Lung Diseases

Treatments: Other: blood specimen; Other: BAL; Other: Urine specimen; Other: BW; Other: EAC

Study type: Observational

Funder types: Other

Identifiers

NCT02549248

1008122

Details and patient eligibility

About

Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically. Despite their widespread use, their true impact on human health remains unknown and poorly studied. NP exposure in humans primarily occurs via inhalation through the respiratory system. The aim of this study is to estimate the relationships between the nanoparticle load in the lung and bronchi and some interstitial lung diseases. In the aftermath of human exposure to asbestos, the pathological consequences of environmental exposure to nanomaterials could be evaluated upon a mineralogical analysis of pulmonary samples.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with an interstitial lung disease assessed on clinical signs and CT scan, requiring a flexible bronchoscopy with a broncho-alveolar lavage.

These patients suffer from:

• Idiopathic interstitial lung diseases such as idiopathic pulmonary fibrosis or sarcoidosis OR
• Interstitial lung diseases of known aetiologies such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.

Written consent

Exclusion criteria

• Flexible bronchoscopy or BAL not possible.
• Pregnant women
• Patients under legal protection.
• Patients with contagious disease (HIV infection, tuberculosis, viral hepatitis)

Trial design

100 participants in 2 patient groups

Idiopathic interstitial diseases

Description:

" Test group ": patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.

Treatment:

Other: Urine specimen

Other: blood specimen

Other: BAL

Other: BW

Other: EAC

Non idiopathic intertitial diseases

Description:

" Control group ": patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions. Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen.

Treatment:

Other: Urine specimen

Other: blood specimen

Other: BAL

Other: BW

Other: EAC